Early-life stress leads to impaired spatial learning and memory in middle-aged ApoE4-TR mice by unknown
RESEARCH ARTICLE Open Access
Early-life stress leads to impaired spatial
learning and memory in middle-aged
ApoE4-TR mice
Lan-yan Lin1,2†, Jing Zhang1,2†, Xiao-man Dai1,2, Nai-an Xiao2, Xi-lin Wu2, Zhen Wei2, Wen-ting Fang2,
Yuan-gui Zhu1,2 and Xiao-chun Chen1,2,3*
Abstract
Background: Apolipoprotein E (ApoE) is a major lipid carrier that supports lipid transport and injury repair in the
brain. The APOE ε4 allele is associated with depression, mild cognitive impairment (MCI) and dementia; however,
the precise molecular mechanism through which ApoE4 influences the risk of disease development remains
unknown. To address this gap in knowledge, we investigated the potential effects of chronic unpredictable mild
stress (CUMS) on ApoE3 and ApoE4 target replacement (ApoE3-TR and ApoE4-TR) mice.
Results: All ApoE-TR mice exposed to CUMS at 3 months old recovered from a depression-like state by the age of
12 months. Of note, ApoE4-TR mice, unlike age-matched ApoE3-TR mice, displayed impaired spatial cognitive
abilities, loss of GABAergic neurons, decreased expression of Reelin, PSD95, SYN and Fyn, and reduced
phosphorylation of NMDAR2B and CREB.
Conclusion: These results suggest that early-life stress may mediate cognitive impairment in middle-age ApoE4-TR
mice through sustained reduction of GABAergic neurons and Reelin expression, which might further diminish the
activation of the Fyn/NMDAR2B signaling pathway.
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Background
Apolipoprotein E (ApoE) is a major lipid carrier that
plays an important role in maintaining lipid homeostasis,
both in the periphery and the brain, and in various
physiological processes, including central nervous sys-
tem development, nerve regeneration and repair, as well
as learning and memory [1, 2]. The human APOE gene
has three polymorphic alleles, namely APOE2, APOE3,
and APOE4. Although various genetic backgrounds and
life experiences may cause differences in adaptability and
response capability of individual brains to stressful events
[3], ApoE4 has been documented to be an age-dependent
and a gene-dose-effect risk factor for late-onset familial
and sporadic Alzheimer’s disease (AD) [4–6] and psychi-
atric disorders, such as depression [7].
Recent studies have reported that early-life symptoms
of depression can increase the risk of cognitive impair-
ment in old age [8–10], and that adverse events in child-
hood have a more severe effect on the depressive
symptoms present in older-age ApoE4 carriers, as com-
pared to ApoE4 non-carriers [11]. Emerging clinical evi-
dences indicate that compared with ApoE4 non-carriers,
depression patients carrying an APOE4 allele have
significantly-reduced hippocampal volume [12]; and pa-
tients with Alzheimer’s disease, who have a life-time his-
tory of Major Depression, have increased hippocampal
plaques and tangles [8]. In addition, a prospective study
of 142 twins found that patients with dementia, tardive
depression, and the APOE4 allele exhibit an increased
risk for AD pathogenesis [13]. Other prospective studies
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also confirm a close association among depression,
APOE genotype and mild cognitive impairment [14, 15].
These findings suggest that there is a positive correlation
between depressive symptoms and cognitive decline in
people carrying one or two APOE4 alleles [16]. However,
the potential mechanisms underlying the relationships
among depression, APOE genotype, and mild cognitive
impairment remain largely unknown.
Previous studies have verified that patients with
schizophrenia or bipolar disorder/manic depression suf-
fer a great loss of GABAergic neurons in their prefrontal
cortex [17]. GABAergic neurons can secrete the glyco-
protein Reelin, which plays an important role in regulat-
ing synaptic plasticity [18]. In the brain, Reelin mainly
binds to two major lipoprotein receptors on the cell
membrane, apolipoprotein E receptors 2 (ApoER2) and
very-low-density lipoprotein receptor (VLDLR) [19].
Binding of Reelin to the receptors induces feed-forward
activation of DAB1, an adaptor protein that interacts
with NPxY motifs in both receptor tails [20]. The clus-
tering of DAB1 activates SRC family tyrosine kinases
(SFKs), then Reelin-activated SFKs phosphorylate the
NMDAR on NR2 subunits, resulting in the potentiation of
NMDAR-mediated Ca2+ influx. Elevated intracellular Ca2+
can activate the transcription factor cyclic AMP response
element binding protein (CREB), thereby potentially initiat-
ing the expression of genes that are important for synaptic
plasticity, neurite growth and dendritic spine development
[20–22]. Deficits in Reelin have been documented to be
closely associated with mental illness, such as schizophrenia
and depression in human subjects [23, 24]; symptoms
of mental illness and cognitive impairment in Reelin-
knockout mice have also been reported [25].
Given existing studies are largely population-based
and the observed phenomena have not been confirmed
in ApoE-TR mouse models, we sought to determine
whether early-life depression in ApoE4 target replace-
ment (ApoE-TR) mice impairs cognitive function
through a loss of GABAergic neurons and perturbations
in the Reelin-ApoER2 signaling pathway. To test this
hypothesis in the current study, we applied a 6-week
chronic unpredictable mild stress (CUMS) procedure to
3-month-old ApoE-TR mice, thereby generating a reli-
able depression model that mimics a human depressive
state [26]. We found that ApoE4-TR mice that under-
went the early CUMS procedure displayed cognitive im-
pairment at 12-months-old and exhibited decreased
GABAergic neurons in the prefrontal cortex and the
dentate gyrus (DG) of the hippocampus. Furthermore,
the expression levels of Reelin and its down-stream
signaling molecules (Src family tyrosine kinases Fyn and
NMDAR receptor subunits 2B) were significantly re-
duced. Taken together, our novel findings demonstrate
that early CUMS may lead to impaired cognitive
function via the Reelin-ApoER2-Fyn signaling pathway
in middle-aged ApoE4-TR mice.
Methods
Animals and experimental protocol
Human ApoE-TR homozygous mice of the C57BL/6 J
background were obtained from the Taconic (www.taconic.
com), in which the expression of the human ApoE2,
ApoE3, or ApoE4 is controlled by the mouse ApoE pro-
moter [27]. The colony was maintained by homozygous
breeding. Young male ApoE3-TR mice (aged 10 weeks,
n = 60) and age-matched ApoE4-TR mice (n = 60) were
respectively randomized into two groups: those main-
tained under chronic stress conditions, the CUMS group
(n = 30), and those maintained under normal conditions,
the control group (n = 30). All animals were housed in
standard plastic cages (4-5 mice per cage) with wood chips
for bedding at 22 ± 1 °C under a relative humidity of 55 ±
5 % and a twelve-hour light/dark cycle (light from
6:00 a.m. to 6:00 p.m.). They were allowed free access to
food and water. All experimental protocols and proce-
dures were approved by the Committee of Institutional
Animal Care and Use of Fujian Medical University and
closely observed the “Guide for the Care and Use of
Laboratory Animals” by the U.S. National Institutes of
Health (NIH Publications No. 80-23, revised in 1996).
All the animals received sucrose preference training
and environmental adaptation for 2 weeks; after which
the CUMS groups underwent the CUMS procedure for
6 weeks. After the intervention, the animals received
behavioral tests for a period of 4 weeks. At the end of
the behavioral tests, some of the mice were sacrificed
as samples; the rest were normally bred to 12 months
and underwent the behavioral tests again before sacri-
fice for further experiments. The time schedule is pro-
vided in Fig. 1.
Chronic Unpredictable Mild Stress (CUMS) procedure
The stress procedure was modified from a previous de-
scription by Willner et al. [26, 28]. In brief, for the
chronic stress group, each mouse was kept in isolation
in a single cage and underwent a variety of mild
stressors: white noise for 12 h, cage tilting for 24 h,
swimming in cold water (18 °C) for 5 min, food
deprivation for 12 h, water deprivation for 12 h, wet
bedding for overnight, and strobe lights for 24 h, restric-
tions in a small tube (10×5×5 cm) for 2 h. The stress
procedure continued for 6 weeks prior to behavioral
tests; the control animals were kept in groups (five mice
per cage) and given ordinary daily care.
Sucrose solution consumption test
As previously described [29, 30], the sucrose preference
training began prior to the stress procedure and the
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sucrose solution consumption test was conducted once a
week during the stress procedure. The detailed test
protocol was as follows: after a 12-h period of water and
food deprivation, the sucrose preference test was per-
formed from 10:00 am to 12:00 am; the animals were
allowed free access to two bottles containing water and
1 % sucrose solution respectively; two hours later, the
volumes of water and sucrose solution consumed were
measured. The amount of sucrose solution ingested as a
percentage of the total liquid was interpreted as the par-
ameter of hedonic behavior.
Behavioral testing
During the behavioral test, the CUMS procedure was
continued without food and water deprivation. All of the
tests were conducted in a test room with relatively dim
lighting (±20 lux) from 8:00 a.m. -11:30 a.m. Mice were
given 30 min to adapt to the environment before the test
began and returned to their original location immedi-
ately after the experiment.
Elevated plus maze test
The elevated plus-shaped maze test was employed as de-
scribed by Pellow [31, 32]. The maze apparatus (50 cm
off the ground) consisted of two open arms (50 × 5 cm;
with ledges, 0.5 × 0.5 cm) and two opposite closed arms
(50 × 5 cm; with walls, 38 cm high), forming a middle
square area (5 × 5 cm), which allows the animals to pass
through the arms freely. Mice were individually placed
in the middle square area and allowed free exploration
for 10 min. Their behaviors were recorded by a video
tracking system (Super Maze V2.0, XinRuan, Shanghai,
China) and the following variables were analyzed: the
frequency and distance animals traveled into the open
arms, closed arms and middle square area. After each
behavioral test, the apparatus was cleaned with 75 %
alcohol-water to remove odors.
Open field test
The open field test (OFT) was designed in accordance
with the procedures described by Heimrich et al. [33].
Each mouse was placed in the middle of an open box
(50× 50 × 50 cm) and the area was divided into 9 squares
of 16.67 cm × 16.67 cm with painted white lines. Activity
was recorded by a digital camcorder (Sony, Japan) and
analyzed using Top Scan software (Super Maze V2.0
XinRuan Information Technology Co. Ltd, Shanghai,
China). Indicators included horizontal movement (the
number of crossings as assessed by the grids marked on
the bottom of the box) and vertical movement (the times
of rearing) during the 10-min test. To eliminate the
interference of animal odor, the box was cleaned with
75 % alcohol between testing sessions.
Tail suspension test
Immediately after the OFT, the tail suspension test
(TST) was performed as described by Crowley et al.
[34]. In brief, we trussed up the mouse tail with a piece
of adhesive tape and fixed it on a hook (about 2 cm away
from tip) and suspended the mouse approximately 28 ±
2 cm off the floor. Then we recorded the duration of be-
havioral immobility of each mouse within a period of
6 min with an automated TST device (Super Maze V2.0,
XinRuan, Shanghai, China). The experiment was con-
ducted according to the following parameters: threshold
1 = 7, gain = 16 times, constant = 0.25, resolution = 200 ms.
Data were analyzed by technicians who were trained but
blind to the experiment protocol.
Morris maze test
The water maze apparatus and procedures have been de-
scribed in our previous research [35]. Briefly, the dark
stainless steel pool was 1.2 m in diameter and 0.5 m high
with a blank nontoxic plastic bottom. A round platform
made of transparent plexiglas (7 cm in diameter) was
placed in the center of the southeast corner. Before tests,
Fig. 1 The time schedule for experimental procedures in ApoE-TR mice. During weeks 10–12, all ApoE3-TR mice (n = 60) and ApoE4-TR mice
(n = 60) received sucrose preference training and environmental adaptation. A group of ApoE3-TR and ApoE4-TR mice underwent the CUMS
procedure during weeks 12–18; all mice underwent behavior testing during weeks 18–22. About 50 % of ApoE3-TR and ApoE4-TR mice were
sacrificed during week 22 with the remaining mice undergoing behavior testing during weeks 48–52 prior to sacrifice
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the circular pool was filled with water to a depth of
35 cm,approximately 2 cm higher than the height of the
platform. The water was rendered opaque by pouring
1500 ml of milk into the pool and the temperature of
the water and the test room was set at 22 ± 2 °C during
the test.
During cognitive spatial ability testing, each animal
took four trials daily for 5 consecutive days. Each trial
was started from a different location and lasted for 60 s,
with the mouse facing the wall of the pool when placed
into the water. The quadrant from which the mouse was
placed into the water in each trial was varied according
to semi-random sequence distribution decisions by
Vorhees & Williams [36]. On locating the platform, the
mouse was left there for 15 s before the next trial. If the
animal failed to locate the platform within 60 s, it was
guided to the platform and allowed to stay there for
15 s. The latency and the travel orbit of reaching the
platform were recorded by the tracking system. On the
sixth day, the learning memory test was conducted with
the platform removed. Each animal was given 60 s to
explore the pool. Mouse performance was recorded by
Smart 2.0 video-tracking software (PanLab, Barcelona,
Spain).
Tissue preparation
Mice were deeply anesthetized with 10 % chloral hydrate
(3 ml/kg) by intraperitoneal injection and perfused via
the left ventricle with ice-cold 0.1 M phosphate-buffered
saline (PBS) (25 ml per mouse). Their brains were rap-
idly removed from the skull and dissected on ice. The
prefrontal cortex and hippocampus of some of the har-
vested brains were isolated and dipped into liquid nitro-
gen and stored at -80 °C. The remaining regions were
fixed in 4 % paraformaldehyde at 4 °C for 48 h and dehy-
drated twice with 30 % sucrose solution at 4 °C for 24 h
each time. The fixed brains were cut into serial sections
(30 um thick) with a freezing microtome (CM1850,
Leica, Germany) and the sections were picked up in
antifreeze liquid (30 % glycerol, 30 % ethylene glycol,
40 % 0.1 M PBS) and stored at -20 °C until use.
Western blot analysis
Tissues were dissected from 3-month-old and 12-
month-old mice and homogenized in a lysis buffer
(30 mM Tris-HCL, 2 mM Na3VO4, 50 mM NaF,
10 mM Na4P2O7, 1 % Triton X-100 and 1 % protease
inhibitor cocktail at pH 7.4). Then, the supernatants
were collected by centrifuging at 16,000 g at 4 °C for
25 min. Protein concentration was determined with the
Bradford assay kit (Bio-Rad, Hercules, CA, USA) and ad-
justed to 2.0 mg/mL with lysis buffer and 6× sample buf-
fer (125 mM Tris, pH 6.8, 0.006 % bromophenol blue,
130 mM dithiothreitol, 10 % sodium dodecyl sulfate and
10 % glycerol). Equal amounts of proteins were heated at
100 °C for 5 min. The total protein lysates were sepa-
rated by 10–12 % sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis (SDS-PAGE) and transferred
to polyvinylidene difluoride (PVDF) membranes (0.25
micrometer) overnight using wet transfer equipment at
90 mA (Bio-Rad Laboratories, Hercules, CA, USA). The
membranes were blocked in 5 % bovine serum albumin
(BSA) in Tris-buffered saline Tween-20 (TBST, pH 7.6,
containing 10 mM Tris, 150 mM NaCl, and 0.1 %
Tween-20) at room temperature (RT) for one hour,
followed by incubation with primary antibodies diluted
in 2.5 % BSA/TBST at 4 °C overnight. After incubation,
the membranes were washed in TBST three times
(10 min per time), and further incubated off light at RT
for one hour with infrared dye-labeled fluorescence
secondary antibodies diluted in TBS (IRD 800cw, goat-
rabbit C40325-02, goat-mouse C40213-01, 1:10000; LI-
COR, USA). Then, the membranes were washed three to
four times in TBST (10 min per time) before fluores-
cence detection with Odyssey Sa color infrared laser im-
aging system (LI-COR, USA) and densitometry analysis
with NIH Image J software. The antibodies used were as
follows: mouse anti-tubulin (Sigma,1:50000), rabbit anti-
PSD-95 (postsynaptic density protein 95) (Millipore,1:2000),
mouse anti-Reelin (Milipore, 1:500), mouse anti-APOE
(Santa-cruz, 1:500), and rabbit anti-NMDAR2B, rabbit
anti-phosphorylation-NMDAR2B, rabbit anti-APOER2,
mouse anti-Fyn (Abcam, 1:1000, respectively), mouse
anti-SYN (synaptophysin) (Millipore 1:10000), rabbit
anti-phosphorylated CREB (Millipore 1:500), rabbit
anti-CREB (Abcam 1:1000).
Immunohistochemistry
For immunodetection of GABAergic neurons and
Reelin, the sections were washed with Tris-buffered sa-
line TBS for 6×10 min and immersed in 3 % H2O2/TBS
to inactivate endogenous peroxidase in the dark for
20 min. Next, they were washed with TBS (3×10 min)
and blocked with TBS containing 0.3 % Triton X-100,
0.25 % bovine serum albumin (BSA), and 5 % goat
serum (GS) at RT for 2 h. Then, they were incubated
overnight at 4 °C with primary antibodies (anti-GABA,
rabbit, 1 : 8000, Sigma or anti-Reelin, mouse, 1:2000,
Millipore) in TBS containing 0.25 % BSA, 2 % normal
goat serum, and 0.3 % Triton X-100. After the incuba-
tion, they were washed with TBST for 6×10 min, and
further incubated at RT for 90 min with biotinylated
secondary antibodies (at 1: 600, Vector Laboratories,
Burlingame, CA, USA). After further washes with TBST
(6×10 min), they were incubated in Vector Elite avidin–
peroxidase dilution (at 1:200) at RT for 60 min. Subse-
quently, the above-treated sections were serially washed
in TBST (3×5 min) and in 0.175 M sodium acetate
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solution (3×5 min) before the staining was revealed with
diaminobenzidine (DAB) and H2O2 diluted in 0.175 M
sodium acetate at RT for 10 min and terminated with
0.175 M sodium acetate promptly. They were then
mounted on glass slides, which had been coated with
poly-lysine and air dried at RT overnight. Finally, they
were dehydrated with graded alcohol and rendered trans-
parent by xylene liquid, and coverslipped with a perman-
ent mounting medium (Vector Laboratories, USA).
The stained sections were observed under a micro-
scope (OlympusBX-51, Olympus, Japan). Image acquisi-
tion was performed with Image-Pro Express 5.1 image
analysis software. For quantitative analysis, we randomly
selected 4–5 mice from each group and measured 3–5
consecutive sections of each mouse. The prefrontal cor-
tex and dentate gyrus (DG) region of the hippocampus
were selected as regions of interest (ROI) and the identi-
cal area within the measuring frame in a 10X objective
lens was labeled. The number of positively-stained neu-
rons in the frame was counted by 100X magnification.
The clear brown cellular boundaries were considered
positive, although positive cells outside the frame were
rejected. “Cells” that were lightly stained or had irregular
shapes were excluded from quantification. Then the
mean value for each mouse was calculated.
Immunofluorescence
For immunofluorescence staining of the Glutamatergic
neurons, the sections were washed with Tris-buffered sa-
line (TBS) for 6×10 min, next blocked with TBS contain-
ing 0.3 % Triton X-100, 0.25 % bovine serum albumin
(BSA), and 5 % donkey serum (DS) at RT for 2 h. Then,
they were incubated overnight at 4 °C with primary anti-
bodies (rabbit anti-VGluT1, Abcam 1:1000) in TBS con-
taining 0.25 % BSA, 2 % normal donkey serum, and
0.3 % Triton X-100. After the incubation, they were
washed with TBST for 6×10 min, and further incubated
at RT for 90 min with fluorescent secondary antibodies
(Alexa Fluor 488-conjugated donkey anti-rabbit IgG,
Invitrogen, 1: 2000). After further washes with TBST
(6×10 min), they were then mounted on glass slides
coated with poly-lysine. Then the prefrontal cortex and
dentate gyrus (DG) region of the hippocampus were se-
lected as regions of interest (ROI) and taken pictures by
the Confocal Microscopy (Zeiss, 780). The Mean fluor-
escence intensity was analyzed in the all groups.
Real-time reverse transcription polymerase chain reaction
Total RNA was extracted from the prefrontal cortex
and hippocampus using TriPure Isolation reagent
(Roche, Mannheim, Germany) according to the manu-
facturer’s protocol and was reverse transcribed using
the Transcriptor First Strand cDNA synthesis kit
(Ferments, Canada). Polymerase chain reaction (PCR)
was performed with Fast Start Universal SYBR Green
Master (Roche), and fluorescence was measured using the
Step-One Plus realtime PCR system (Life Technologies
Applied Biosystems, Grand Island, NY). The following
primer sets were used: Reelin (NM_011261, sense 5-
GGACTAAGAATGCTTATTTCC-3 and anti-sense 5-
GGAAGTAGAATTCATCCATCAG -3) and GAPDH
(NM_008084, sense 5-CAGTGGCAAAGTGGAGATT
GTTG -3 and antisense 5- CTCGCTCCTGGAAGATG
GTGAT -3). Each reaction was run in triplicate. The
efficiency of all experiments fell between 95 and 105 %,
and all gene measures displayed normal melt curves.
Fold changes were calculated by 2−Δ(ΔCt) [ΔCt = Ct
(target gene) – Ct (GAPDH); Δ(ΔCt) =ΔCt (experimental
groups)−mean ΔCt (3-month control-E3 groups)].
Statistical analysis
Data were analyzed with SPSS 13.0 statistical software and
quantitative data were expressed as mean ± SEM. Data
sets were first tested for normal distribution and then
compared using,one-factor and two-factor ANOVA. Stat-
istical significance was set at p < 0.05.
Results
CUMS procedure successfully induces depression-like
behaviors in 3-month-old ApoE-TR mice
To assess the impact of the CUMS procedure, we evalu-
ated the weight, sucrose consumption and behavior of
ApoE3/4-TR mice undergoing CUMS compared to con-
trols. While the weights of mice in the control groups
steadily increased during weeks 12–18, the weights of
mice undergoing CUMS leveled off, with a significant
difference between the control groups and the ApoE4-
TR mice observed in the fifth week (for ApoE3, 24.73 ±
0.28 vs. 28.41 ± 0.35, p < 0.01; for ApoE4, 24.74 ± 0.52 vs.
28.41 ± 0.43, p < 0.01) (Fig. 2a). Sucrose consumption
preference in the CUMS groups gradually decreased,
with the difference between the CUMS groups and
the controls becoming significant in the third week
(for ApoE3, 61.63 % ±2.95 % vs 84.12 % ± 2.08 %, p < 0.01;
for ApoE4, 61.94 % ±2.73 % vs. 83.44 % ±1.89 %, p < 0.01)
and greatly intensifying in the sixth week (for ApoE3,
60.41 % ±1.15 % vs. 83.22 % ±2.86 %, p < 0.001; for ApoE4,
60.17 % ±1.20 % vs. 84.25 % ± 0.57 %, p < 0.001) (Fig. 2b).
To assess whether the CUMS groups exhibit
depression-like behavior, an elevated plus maze, open
field test and tail suspension test were used. Compared
with the control groups, the CUMS groups spent signifi-
cantly less time in the open arms of the elevated plus
maze (for ApoE3, 7.87 % ± 0.45 % vs. 16.74 % ± 1.42 %,
p < 0.05; for ApoE4, 6.457 % ± 0.63 % vs. 19.35 % ±
0.93 %, p < 0.001) (Fig. 2c), and entered less frequently
into the open arms after 6 weeks of CUMS interven-
tion (for ApoE3, 14.10 % ± 0.91 % vs. 28.87 % ±
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1.72 %, p < 0.01; for ApoE4, 13.07 % ± 1.15 % vs.
33.33 % ± 2.48 %, p < 0.001) (Fig. 2d). Results from the
open field test demonstrated that the CUMS groups
exhibited significantly reduced horizontal movement
(for ApoE3, 95.83 ± 9.13 vs. 155.9 ± 4.14, p < 0.001; for
ApoE4, 109.3 ± 10.40 vs. 146.8 ± 2.89, p < 0.01), vertical
movement (for ApoE3, 15.77 ± 0.66 vs. 30.73 ± 1.12, p <
0.001; for ApoE4, 15.31 ± 1.01 vs. 28.0 ± 1.43, p < 0.001)
and total movement (for ApoE3, 107.9 ± 3.86 vs. 193.5 ±
3.87, p < 0.001; for ApoE4, 97.36 ± 7.14 vs. 186.9 ±
3.16, p < 0.001) (Fig. 2e, f and g). Furthermore, the tail
suspension test showed that the CUMS groups’ resting
time, or the amount of time spent immobile, was signifi-
cantly longer than the control groups, indicating a
depression-like state (for ApoE3, 63.39 % ± 6.49 % vs.
42.39 % ±4.68 %, p < 0.05; for ApoE4, 72.33 % ± 5.66 % vs.
35.36 % ± 4.50 %, p < 0.01) (Fig. 2h). No significant differ-
ence was observed between the CUMS-treated ApoE3
(CUMS-E3) group and ApoE4 (CUMS-E4) groups in the
above-mentioned three tests. Taken together, these data
indicate that CUMS treatment successfully induces
depression-like behaviors in ApoE-TR mice.
In order to further investigate changes in learning and
memory, we performed the Morris water maze test,
which measures hippocampus-dependent spatial naviga-
tion and reference memory. With the advancing training
days, the escape latency of the control groups did grad-
ually decrease as shown in Fig. 2i; however, the escape
latency of the CUMS groups did not change regardless
of training time. (for both ApoE3 and ApoE4, p < 0.01)
Fig. 2 CUMS successfully induced depression-like behaviors in 3-month-old ApoE-TR mice. a-b Weight change and the percentage of sucrose
preference in 3 M ApoE-TR mice during 6 weeks of CUMS. c-d The percentage of time spent and number of entries into the open arms for 3 M
ApoE-TR mice in the elevated plus maze test. e-g The extent of locomotion (Horizontal), rearing (Vertical) and total movement (Horizontal +
Vertical) for 3 M ApoE-TR mice in the open field test. h The percentage of resting time for 3 M ApoE-TR mice during the 6 min tail suspension
test. i Escape latency in 3 M ApoE-TR mice for the first 5 days during the Morris maze test. j The swimming speed of 3 M ApoE-TR mice for the 5
days during the Morris maze test. k-l) The percentage of time spent in target quadrant and the number of times crossing the former platform
position during the last day of 3 M ApoE-TR mice in the Morris maze test. m Representative swimming tracks in the Morris water maze for days
1–5 of training and day 6 of probe trial. N = 12 per group, expressed as mean ± SEM. The Figure a, b, i, j used the two-factor ANOVA of statistical
methods, and the Figure c-h, k, l used the one-factor ANOVA of statistical methods. & p < 0.05, && p < 0.01, &&& p < 0.001, CUMS E3 vs. Con E3.
*p < 0.05, **p < 0.01, ***p < 0.001, CUMS E4 vs. Con E4
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(Fig. 2i). Meanwhile, the swimming speed of the CUMS
groups was significantly lower than the control groups
(p < 0.001) (Fig. 2j). In the probe trial with the platform
removed, the CUMS groups spent far less time in the
target quadrant (for ApoE3, 24.07 % ± 1.88 % vs.
51.13 % ± 6.47 %, p < 0.01; for ApoE4, 21.60 % ± 4.17 %
vs. 52.36 % ± 5.83 %, p < 0.01) (Fig. 2k). Additionally, the
number of times CUMS mice crossed the platform pos-
ition was significantly less than the control groups (for
ApoE3, 0.75 ± 0.21 vs. 4.58 ± 0.37, p < 0.001; for ApoE4,
0.66 ± 0.28 vs. 3.00 ± 0.47, p < 0.001) (Fig. 2l). Swimming
tracks of training and probe trials were recorded for each
day and each genotype (representative example, Fig. 2m).
Therefore, these data indicate that the ApoE-TR mice
shown a dysfunction of spatial memory in the Morris water
maze after the CUMS intervention. But there was no sig-
nificant difference between CUMS-E3 and CUMS-E4.
ApoE4-TR mice recover from depression but develop
cognitive impairment by 12 months old
After the initial behavioral tests, some of the ApoE-TR
mice were sacrificed and brains were harvested for sub-
sequent experiments. The remaining ApoE-TR mice
were raised without additional treatment to 12 months
and underwent a second round of behavioral tests to re-
assess behavior and cognitive ability.
At 12 months old, no significant difference was
observed between the control and CUMS groups in the
elevated plus maze test (the time percentage and the fre-
quency percentage of entering the open arm), open field
Fig. 3 ApoE4-TR mice recovered from depression but developed cognitive impairment by 12 months old. a-b The percentage of time spent and
number of entries into the open arms for 12 M ApoE-TR mice in the elevated plus maze test. c-e The extent of locomotion (Horizontal), rearing
(Vertical) and total movement (Horizontal + Vertical) for 12 M ApoE-TR mice in the open field test. f The percentage of resting time for 12 M
ApoE-TR mice during the 6 min tail suspension test. g Escape latency of 12 M ApoE-TR mice during the 5 days of training in the Morris maze test.
h The swimming speed of 12 M ApoE-TR mice for the first 5 days in the Morris maze test. i-j The percentage of time spent in target quadrant
and the number of platform-position crossings for 12 M ApoE-TR mice during the sixth day of the Morris maze test. k Representative swimming
tracks in the Morris water maze for days 1–5 of training and day 6 of probe trial. N = 10 per group, expressed as mean ± SEM. The Figure a, -f, i, j
and the Figure g, h used the one-factor ANOVA and two-factor ANOVA of statistical methods respectively.*p < 0.05 **p < 0.01, ***p < 0.001, CUMS
E4 vs. Con E4. # p < 0.05, ##p < 0.01, ### p < 0.001, CUMS E4 vs. CUMS E3
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test (the horizontal movement, the vertical movement
and total movement), and tail suspension test (resting
time percentage) (p > 0.05) (Fig. 3a-b, Fig. 3c-e, Fig. 3f,
respectively), suggesting that ApoE-TR mice recover from
depression after CUMS intervention is terminated.
For the Morris water maze test during the 12th month,
the escape latency of the CUMS-E4 group was signifi-
cantly greater than that of the CUMS-E3 group (p < 0.01
for day 3 and day 5 and p < 0.05 for day 4) and the con-
trol groups (for the control-E4 group, p < 0.01 for day 4;
for the control-E3 group, p < 0.05 for day 4) (Fig. 3g).
But the swimming speeds of all the groups did not differ
noticeably from one another (Fig. 3h). The percentage of
time spent in the target quadrant for the CUMS-E4
group decreased markedly in comparison with that of
the CUMS-E3 group and the control group (for the
CUMS-E3 group, 25.32 % ± 1.88 % vs. 45.76 % ± 4.28 %,
p < 0.001; for the control-E4 group, 25.32 % ± 1.88 % vs.
44.50 % ± 2.51 %, p < 0.001) (Fig. 3i). The CUMS-E4
group crossed over the area where the platform was ini-
tially positioned markedly fewer times than the CUMS-
E3 group and the control-E4 group (for the CUMS-E3
group, 0.66 ± 0.16 vs. 4.22 ± 0.95, p < 0.01; for the
control-E4 group, 0.66 ± 0.16 vs. 5.25 ± 0.70, p < 0.001)
(Fig. 3j). Swimming tracks during training and probe tri-
als were recorded for each day and each genotype
(representative example, Fig. 3k). No significant differ-
ence was found between the CUMS-E3 group and the
control groups. Taken together, these results indicate
that the CUMS-E4 mice can recover from a depressive
state, but, unlike the CUMS-E3 group, their cognitive
function appears to be impaired at middle-age.
The number of GABAergic neurons, Glutamatergic
neurons and expression of Reelin is decreased in the
prefrontal cortex and hippocampus of 12-month-old
ApoE4-TR mice that underwent early-life CUMS
intervention.
GABAergic neurons, which are widely distributed in the
prefrontal cortex and dentate gyrus (DG) region of the
hippocampus, play critical roles in cognition and depres-
sion [37] and can secrete Reelin protein [38]. In order to
assess the prevalence of GABAergic neurons and Reelin
in controls and the CUMS group, we examined the ex-
pression of GABA and Reelin by immunohistochemistry.
As shown in Fig. 4 (with brown positive staining for
GABAergic neurons), the number of GABA-positive
neurons in the prefrontal cortex of the 3-month-old
CUMS-E3 and age-matched CUMS-E4 group was less
than that of the age-matched control groups (for ApoE3,
115.5 ± 6.26 vs. 234.8 ± 7.91, p < 0.001; for ApoE4, 107.0
± 4.35 vs. 237.2 ± 8.93, p < 0.001). However, the number
Fig. 4 Decreased GABAergic neurons in the prefrontal cortex of 12-month-old ApoE4-TR mice that underwent early-life CUMS intervention.
Immunohistochemical staining of anti-GABA in the prefrontal cortex of 3-month-old and 12-month-old ApoE-TR mice. The dark brown dots
represent the anti-GABA–positive GABAergic neurons. Magnified areas indicated by boxes. N = 5 per group, expressed as mean ± SEM. one-factor
ANOVA of statistical methods was used. &&& p < 0.001, ### p < 0.001, ***p < 0.001. Scale bars are 200 um
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of GABA-positive neurons in the 12-month-old
CUMS-E4 group was significantly less than that of
the age-matched CUMS-E3 and control groups (for the
CUMS-E3 group, 82.83 ± 4.46 vs. 158.3 ± 8.38, p < 0.001;
for the control-E4 group, 82.83 ± 4.46 vs. 192.3 ± 5.41,
p < 0.001; for the control-E3 group, 82.83 ± 4.46 vs.
194.2 ± 3.73, p < 0.001). Consistent with the staining
results of the prefrontal cortex, the number of GABA-
positive neurons in the hippocampal dentate gyrus (DG)
region for the 12-month-old CUMS-E4 group was signifi-
cantly lower than that of the age-matched CUMS-E3 and
control groups (for the CUMS-E3 group, 27.83 ± 3.24
vs. 45.33 ± 2.04, p < 0.001; for the control-E4 group,
27.83 ± 3.24 vs. 54.38 ± 3.38, p < 0.001; for the control-
E3 group, 27.83 ± 3.24 vs. 54.83 ± 2.34, p < 0.001)
(Fig. 5). Therefore, our data suggest that the number
of GABAergic neurons in ApoE4-TR mice is irrevers-
ibly reduced following early-life CUMS intervention.
The expression of Reelin in the 3-month-old CUMS-
E3 group and CUMS-E4 group was greatly reduced
when compared with that of the age-matched control
groups either in the prefrontal cortex (Fig. 6) (for ApoE3,
332.0 ± 15.29 vs. 574.2 ± 17.02, p < 0.001; for ApoE4,
350.8 ± 9.71 vs. 540.8 ± 12.23, p < 0.001) or in the DG re-
gion of the hippocampus (Fig. 7) (for ApoE3, 67.95 ± 1.18
vs. 100.8 ± 4.36, p < 0.001; for ApoE4, 65.65 ± 3.60 vs.
102.3 ± 5.03, p < 0.001). Compared with other groups,
Reelin expression at the 12th month for the CUMS-E4
group was decreased in both the prefrontal cortex (for the
CUMS-E3 group, 318.2 ± 9.38 vs. 417.6 ± 12.50, p < 0.001;
for the control-E4 group, 318.2 ± 9.38 vs. 534.0 ± 7.53,
p < 0.001; for the control-E3 group, 318.2 ± 9.38 vs.
556.6 ± 6.39, p < 0.001) and the DG of the hippocam-
pus (for the CUMS-E3 group, 62.45 ± 2.92 vs. 82.25 ±
2.95, p < 0.001; for the control-E4 group, 62.45 ± 2.92
vs. 98.20 ± 1.59, p < 0.001; for the control-E3 group,
62.45 ± 2.92 vs. 98.00 ± 2.28, p < 0.001). At 3 months
old, the mRNA level of Reelin in the CUMS groups
was markedly less that of the control groups either in
the prefrontal cortex (p < 0.05) (Fig. 6c) or in the
hippocampus (p < 0.05) (Fig. 7c). At 12 months, only
the CUMS-E4 group exhibited a decreased Reelin mRNA
level, either in the prefrontal cortex (for the CUMS-E3
group, 0.134 ± 0.052 vs. 1.063 ± 0.256, p < 0.05) or in the
hippocampus (for the CUMS-E3 group, 0.165 ± 0.0365 vs.
0.766 ± 0.175, p < 0.05). These results suggest that the ex-
pression of Reelin is irreversibly diminished in the ApoE4-
TR mice following early-life CUMS intervention.
Due to the excitatory and inhibitory balance of neur-
onal network activity is essential for normal brain func-
tion and may be of particular importance to memory
[39]. The immunofluorescent staining of the presynaptic
Fig. 5 Decreased GABAergic neurons in the hippocampus of 12-month-old ApoE4-TR mice that underwent early-life CUMS intervention.
Immunohistochemical staining of anti-GABA in the hippocampus of ApoE-TR mice at 3 months and 12 months. The dark brown dots represent
the anti-GABA -positive GABAergic neurons. Magnified areas indicated by boxes. N = 6 per group, expressed as mean ± SEM. one-factor ANOVA of
statistical methods was used. &&& p < 0.001, ### p < 0.001, ***p < 0.001. Scale bars are 200 um
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glutamatergic vesicular transporter (VGluT1), one of the
significant Glutamatergic neurons marker, was detected
in the prefrontal cortex and the DG of the hippocampus.
As shown in Fig. 8 (with green positive staining), the mean
fluorescence intensity of VGluT1 in the prefrontal cortex
of 3-month-old CUMS-E3 and age-matched CUMS-E4
group was less than that of the age-matched control
groups. However, the mean fluorescence intensity of
VGluT1 in the 12-month-old CUMS-E4 group was sig-
nificantly less than that of the age-matched CUMS-E3
and control groups. Consistent with the staining results of
the prefrontal cortex, the mean fluorescence intensity of
VGluT1 in the DG of the hippocampus for the 12-month-
old CUMS-E4 group was significantly lower than that of
the age-matched CUMS-E3 and control groups. There-
fore, our data suggest that the number of Glutamatergic
neuron in ApoE4-TR mice is irreversibly reduced follow-
ing early-life CUMS intervention.
Reelin-Fyn-NMDAR2B signaling pathway activity is
decreased in the prefrontal cortex and hippocampus of
12-month-old ApoE4-TR mice that underwent early-life
CUMS intervention
Given the Reelin-ApoER2-Fyn-NMDA signaling pathway
plays an important role in learning and memory [40], we
examined the expression of Reelin, ApoE, ApoER2, Fyn,
PSD95, SYN, NR2A, and phosphorylated NR2B and
phosphorylated-CREB in the prefrontal cortex and
hippocampus by Western-blotting. In the prefrontal
cortex and hippocampus, the level of ApoE and
ApoER2 in the ApoE4 control and stress groups was
significantly lower than that of the ApoE3 groups (p < 0.05
and p < 0.01, respectively) (Fig. 9). At the age of 12 months,
the level of Reelin (170Kda) in the CUMS-E4 group was
significantly lower compared with that of the CUMS-E3
group (41.77 % ±3.11 % decline, p < 0.05 for prefrontal-
cortex and 57.83 % ±4.27 % decline, p < 0.01 for hippo-
campus) and of the control-E4 group (33.53 % ±3.10 %
decline, p < 0.05 for prefrontal-cortex and 29.44 % ±4.27 %
decline, p < 0.05 for hippocampus). The level of PSD95,
SYN and Fyn in the hippocampus of the CUMS-E4 group
was lower when compared to the CUMS-E3 group
(for PSD95, 31.77 % ±4.24 % decline, p < 0.05; for
Syn, 30.50 % ±3.92 % decline, p < 0.05; for Fyn,
54.22 % ±4.71 % decline, p < 0.001) and the control-
E4 group (for PSD95, 40.20 % ±4.24 % decline, p < 0.01;
for Syn, 45.60 % ±3.92 % decline, p < 0.01; for Fyn,
43.67 % ±4.71 % decline, p < 0.001). The expression of
PSD95, SYN and Fyn in the prefrontal cortex of the
CUMS-E4 group were also diminished when compared
Fig. 6 Decreased expression of Reelin in the prefrontal cortex of 12-month-old ApoE4-TR mice that underwent early-life CUMS intervention. a
Anti-Reelin immunohistochemical staining in the prefrontal cortex of ApoE-TR mice at 3 months and 12 months. The anti-Reelin-positive neurons
were shown as dark brown dots or claws. b The quantified positively-stained Reelin in the prefrontal cortex. N = 5 per group, expressed as mean ±
SEM. &&& p < 0.001, ### p < 0.001, ***p < 0.001. Scale bars are 200 um. c The expression of Reelin mRNA analyzed by real time RT-PCR in the
prefrontal cortex. N = 3 per group, expressed as mean ± SEM. one-factor ANOVA of statistical methods was used. & p < 0.05, # p < 0.05, *p < 0.05
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with those of the CUMS-E3 and Control-E4 group, al-
though the difference was not significant (p > 0.05). The
level of p-NR2B in the CUMS-E4 group was less than
that of the CUMS-E3 group (16.97 % ±3.32 % de-
cline, p > 0.05 for prefrontal-cortex and 44.67 % ±3.85 %
decline, p < 0.01 for hippocampus) and of the Control-E4
group (36.25 % ±3.32 % decline, p < 0.05 for prefrontal-
cortex and 46.85 % ±3.84 % decline, p < 0.01 for hippo-
campus). However, the expression of NMDAR2B, either
in the prefrontal cortex or in the hippocampus, was not
significantly different among all groups. We also checked
the levels of phosphorylated CREB and total CREB, which
are the downstream proteins of the Reelin-Fyn-NR2B sig-
naling pathway. The level of p-CREB in the 12 M CUMS-
E4 group was less than that of the CUMS-E3 group
(26.05 % ±0.97 % decline, p < 0.05 for prefrontal-cortex
and 24.02 % ±2.52 % decline, p < 0.05 for hippocampus)
and of the Control-E4 group (28.60 % ±0.97 % de-
cline, p < 0.05 for prefrontal-cortex and 32.89 % ±2.52 %
decline, p < 0.05 for hippocampus). However, the ex-
pression of total CREB, either in the prefrontal cortex
or in the hippocampus, was not significantly different
among all groups. These results indicate the activity of the
Reelin-ApoER2-Fyn-NMDAR2B pathway is decreased in
the 12-month-old CUMS-E4 mice.
Discussion
In the present study, we created a depression model by
treating 3-month-old ApoE-TR mice with chronic
unpredictable mild stress (CUMS). After the CUMS
intervention, the mice were able to recover from depres-
sion by the age of 12 months. However, 12-month-old
CUMS-E4 mice displayed a decline in spatial cognitive
abilities when compared with CUMS-E3 mice of the same
age. Interestingly, we found the number of GABAergic
neurons and Glutamatergic neurons and the expression of
Reelin in the prefrontal cortex and hippocampus were
reduced in CUMS-E4 mice. Additionally, the expression
of Reelin and Fyn and the phosphorylation of NMDAR2B
and CREB, all of which are critical to proper maintenance
of cognitive pathways, were also decreased in the CUMS-
E4 mice.
Our study demonstrates 3-month-old ApoE-TR mice,
having undergone CUMS intervention, performed worse
in the Morris maze test than the control groups (Fig. 2i,
Fig. 2k-m), and their exercise capacity (swimming speed)
Fig. 7 Decreased expression of Reelin in the hippocampus of 12-month-old ApoE4-TR mice that underwent early-life CUMS intervention. a
Anti-Reelin immunohistochemical staining in the DG region of the hippocampus of 3-month-old and 12-month-old ApoE-TR mice. The anti-Reelin-
positive neurons were shown as dark brown dots or claws. b The quantified positively-stained Reelin in the DG region of the hippocampus. N = 6 per
group, expressed as mean ± SEM. &&& p < 0.001, ### p < 0.001, ***p < 0.001. Scale bars are 200 um. c The expression of Reelin mRNA analyzed by real
time RT-PCR in the hippocampus. n = 3 per group, expressed as mean ± SEM. one-factor ANOVA of statistical methods was used. & p < 0.05, # p < 0.05,
*p < 0.05, **p < 0.01
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also decreased (Fig. 2j). These results may represent a
manifestation of depression symptoms or real cognitive
impairment. When the mice were allowed to recover
after the CUMS intervention, their depression-like be-
havior disappeared (Fig. 3a-f ) and exercise capacity was
restored (Fig. 3h) by the age of 12 months. The CUMS-
E3 group’s scores on the Morris maze test were not sig-
nificantly different from those of the control group,
suggesting that the decline in performance and de-
creased motor ability of the young ApoE-TR mice in the
Morris water maze test represented a pseudo-dementia,
resulting from the CUMS intervention. These findings are
consistent with clinical studies of depression patients who
often manifest symptoms of pseudo-dementia [41, 42].
Recent studies [43, 44] have reported that it takes the
naturally-aging ApoE4-TR mice 14–16 months to dis-
play cognitive decline. In the current study, the scores of
12-month-old CUMS-E4 mice in the Morris maze test
(including escape latency, target quadrant time and
number of crossings, as shown in Fig. 3g and Fig. 3i-k)
were significantly lower than those of the control groups
and CUMS-E3 mice, suggesting that early-life CUMS
intervention accelerates the decline of spatial learning
and memory of ApoE4-TR mice.
Our findings are consistent with the clinical observa-
tion that early-life depression in ApoE4 carriers leads to
impaired cognitive function in older age. Clinical studies
have shown that a history of depressive symptoms [45]
and the APOE4 genotype [3] are independent contribu-
tors to cognitive decline (CD). Moreover, the influence
of depression on CD is greater in individuals with the
APOE4 genotype; depression and the APOE4 genotype
may act concomitantly to affect an individual’s cognitive
reserve capacity in old age [46].
Consistent with clinical autopsy of patients with de-
pression [17, 47, 48] and depression animal models [37],
which reveal a great loss of GABAergic neurons in the
brain, we found that the GABAergic neurons in young
ApoE-TR mice were greatly reduced following CUMS
intervention. Of note, the number of GABAergic neu-
rons in CUMS-E3 mice could be partially restored by
12 months of age; however, the number of GABAergic
neurons in the hippocampus of 12-month-old CUMS-E4
mice was significantly less than that of CUMS-E3 mice.
Fig. 8 Decreased the levels of Glutamatergic neurons in the prefrontal cortex and the DG of the hippocampus in the 12-month-old ApoE4-TR mice
that underwent early-life CUMS intervention. Immunofluorescent staining of the presynaptic gutamatergic transporter VGluT1 in the prefrontal cortex
and the DG of the hippocampus in the ApoE-TR mice. Representative images (X20 magnification) are presented on the left. Quantification of the
results (the mean intensity) was performed by computerized image analysis is shown on the right. N = 6 per group, expressed as mean ± SEM.,
one-factor ANOVA was adopt to analysis the data. &&& p < 0.001, # p < 0.05, *** p < 0.001, ** p < 0.01. Scale bars are 100 um
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We also found that the number of the Glutamatergic
neurons shows paralleled with the change of GABAergic
neurons in the prefrontal cortex and the DG region of
the hippocampus, some studies have reported that the
social defeat depressive model mice have appeared the
dysfunctional activities of GABAergic and Glutamatergic
neurons in the prefrontal cortex [39]. These results fur-
ther confirmed the early intervention has a greatly im-
pact in the ApoE4-TR mice. The level of ApoE in the
prefrontal cortex and hippocampus of the ApoE4 groups
was significantly lower than that of the ApoE3 groups,
so we speculate that after the CUMS treatment, the re-
duced ability of ApoE4-TR mice to repair GABAergic
neurons may be associated with lower ApoE levels in the
brain. Such findings are consistent with studies reporting
that compared to ApoE3, ApoE4 possesses weaker
damage-repair ability to fight against acute inflammatory
reaction and apoptosis [49]. Huang et al. reported
[50–53] that female apoE4-TR mice had an age-dependent
decline in hilar GABAergic interneurons that correlated
with the extent of learning and memory deficits in aged
mice, but not in the male apoE4-TR mice. Meanwhile, in-
hibitory interneuron progenitor transplantation or GABAA
receptor potentiator pentobarbital (PB) restores normal
learning and memory in ApoE4-TR mice [54, 55]. Huang’s
research illustrated that decline in GABA signaling play an
important role in the cognitive dysfunction in ApoE4-TR
mice, which is consistent with our results. In order to re-
move the effect of estrogen and estrous cycle on the emo-
tional and cognitive processes in the female mice, only the
male apoE4-TR mice were used in our study.
Given GABAergic neurons secrete Reelin [56], in the
prefrontal cortex and hippocampus [18], we sought to
explore the relationship between the two. Our immuno-
histochemical results showed that the decrease in
positively-stained Reelin ran parallel with that of the
GABAergic neurons in both the prefrontal cortex and
the DG of the hippocampus. Reelin is an extracellular
matrix protein with molecular weight varying from
410Kda, 330Kda, 170Ka or lower. In our study, only the
Fig. 9 Decreased expression of Reelin-Fyn-NMDAR2B in the prefrontal cortex and hippocampus of 12-month-old ApoE4-TR mice that underwent
early-life CUMS intervention. The levels of Reelin (170Kd), ApoE, ApoER2, PSD95, SYN, Fyn, p-NR2B, NR2B, p-CREB and CREB were detected respectively
by Western blot in the prefrontal cortex and hippocampus. N = 6 per group, expressed as mean ± SEM. one-factor ANOVA was used to analysis the
data. *p < 0.05, **p < 0.01, ***p < 0.001, # p < 0.05, ## p < 0.01, ### p < 0.001
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band of 170Kda Reelin were detected by western-blot,
however, all fragments were detected by immunohisto-
chemical staining and qPCR. In 3-month-old CUMS
ApoE3/4 mice, the Reelin-positive stained and mRNA of
Reelin were significantly lower than that in the control,
there was no obviously difference in the protein of
Reelin (170 kDa) detected by western-blot. Of note, we
found that the full Reelin (immunohistochemical and
qPCR) and 170 kDa Reelin (western blot) of middle-
aged ApoE4 mice were significant reduced in the brain.
Taken together, these findings suggest that the reduction
of GABAergic neurons decreases the synthesis of Reelin,
rather than increasing its degradation, in the 12-month-
old CUMS-E4 group.
Although ApoE and Reelin competitively bind to
ApoER2 on the cell membrane [19, 40], our research in-
dicates that the expression of ApoE and ApoER2 re-
mains unaffected by stress and age-related changes. In
the brain, the binding of Reelin to ApoER2 activates the
SRC family tyrosine kinases (Fyn) and leads to the phos-
phorylation of NR2B, resulting in an increased calcium
influx and activation of downstream signaling pathways
associated with cognitive function [20, 40]. Our results
reveal that in the hippocampus of 12-month-old CUMS
ApoE4-TR mice, levels of Fyn, Syn, PSD95, phosphory-
lated NR2B and phosphorylated CREB were significantly
lower than those of other groups. Our previous studies
have found the level of NR2B in E4FAD mice (generated
by crossing 5xFAD mice and h-APOE4-TR mice) were
significantly decreased in the hippocampus [57]. There-
fore, we speculate that decreased expression of Reelin
may lead to lowered activation of downstream Fyn and
declined phosphorylation of NR2B.
Conclusions
Herein the current study demonstrates that early life
stress leads to spatial learning and memory decline in
middle-aged ApoE4-TR mice. CUMS intervention also
causes a loss of GABAergic neurons and a reduced syn-
thesis of Reelin in the prefrontal cortex and hippocam-
pus that is evident in middle-aged ApoE4-TR mice. The
decreased level of Reelin impairs the activation of the
Fyn-NMDAR2B-CREB signaling pathway, which leads to
the cognitive impairment of ApoE4-TR mice (Fig. 10). This
study further confirms the clinical relationship among
ApoE4, depression and cognitive impairment and provides
insight regarding the mechanisms linking early life stress to
cognitive impairment in middle-aged ApoE4-TR mice. Fu-
ture studies are needed to investigate the mechanism(s)
through which early-life stress induces a sustained reduc-
tion of GABAergic neurons in ApoE4-TR mice.
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